Compounders get version of PDUFA

Share this article:

The FDA is looking to get compounders to fill the inspection kitty. Regulatory Focus reports that the FDA has issued draft guidance that would allow the agency to collect fees from compounders, much as it collects PDUFA fees to fund drug reviews. RF notes that lawmakers approved the fee last fall, following a compounding crisis which killed more than 60 people, and during which the FDA said it lacked funding and authority to supervise compounders.

The approved legislation, known as the Drug Quality and Security Act, gave the FDA regulatory authority over what were deemed “outsourcing facilities.”

The fees described in today's RF pay for this supervision and include an annual $15,000 "establishment fee" ($5,000 for small businesses) and a $15,000 re-inspection fee. The guidance also includes an incentive: register as an oursourcing facility before October 1—the end of FY2014—and you don't have to pay that year's fees. These firms would still have to pay FY2015 fees.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.